Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy

Vinaya Simha, Lidia S. Szczepaniak, Anthony J. Wagner, Alex M. Depaoli, Abhimanyu Garg

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

OBJECTIVE - To investigate whether leptin-induced improvements in glycemic control, hyperlipidemia, and insulin sensitivity in hypoleptinemic patients with generalized lipodystrophies are accompanied by reduction in intrahepatic and intramyocellular lipid (IMCL) accumulation. RESEARCH DESIGN AND METHODS - We examined the effects 8-10 months of subcutaneous leptin replacement therapy on insulin sensitivity, IMCL, and intrahepatic lipid content in two patients with acquired generalized lipodystrophy and one patient with congenital generalized lipodystrophy. All patients had extreme lack of body fat, low plasma leptin levels, and elevated serum triglycerides, but only two had diabetes. Insulin sensitivity was measured by a high-dose (0.2 IU/kg) insulin tolerance test, as well as by hyperinsulinemic-euglycemic glucose clamp studies in two patients. IMCL and intrahepatic lipid content were measured by 1H magnetic resonance spectroscopy. All measurements were obtained before and during 2-10 months of leptin therapy. RESULTS - Glycemic control and lipoprotein levels markedly improved with leptin therapy in the two diabetic patients, and a slight improvement in lipoprotein levels was seen in the nondiabetic patients. Insulin stimulated glucose uptake during 60-120 min of the euglycemic clamp studies, and the rate of glucose disappearance during the insulin tolerance test nearly doubled with leptin therapy. As compared with the baseline period, after 8-10 months of leptin therapy, the mean intrahepatic lipid content was reduced by ∼80% and the IMCL content was reduced by ∼42%. CONCLUSIONS - Reduction in IMCL and intrahepatic lipid content may partly explain leptin-induced improvement in insulin sensitivity in patients with generalized lipodystrophy.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalDiabetes care
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Congenital Generalized Lipodystrophy
Leptin
Lipids
Glucose Clamp Technique
Insulin Resistance
Insulin
Lipoproteins
Therapeutics
Glucose
Hyperlipidemias
Adipose Tissue
Triglycerides
Research Design
Magnetic Resonance Spectroscopy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. / Simha, Vinaya; Szczepaniak, Lidia S.; Wagner, Anthony J.; Depaoli, Alex M.; Garg, Abhimanyu.

In: Diabetes care, Vol. 26, No. 1, 01.01.2003, p. 30-35.

Research output: Contribution to journalArticle

Simha, Vinaya ; Szczepaniak, Lidia S. ; Wagner, Anthony J. ; Depaoli, Alex M. ; Garg, Abhimanyu. / Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. In: Diabetes care. 2003 ; Vol. 26, No. 1. pp. 30-35.
@article{6166f536342b4811842cad62ae9adfe6,
title = "Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy",
abstract = "OBJECTIVE - To investigate whether leptin-induced improvements in glycemic control, hyperlipidemia, and insulin sensitivity in hypoleptinemic patients with generalized lipodystrophies are accompanied by reduction in intrahepatic and intramyocellular lipid (IMCL) accumulation. RESEARCH DESIGN AND METHODS - We examined the effects 8-10 months of subcutaneous leptin replacement therapy on insulin sensitivity, IMCL, and intrahepatic lipid content in two patients with acquired generalized lipodystrophy and one patient with congenital generalized lipodystrophy. All patients had extreme lack of body fat, low plasma leptin levels, and elevated serum triglycerides, but only two had diabetes. Insulin sensitivity was measured by a high-dose (0.2 IU/kg) insulin tolerance test, as well as by hyperinsulinemic-euglycemic glucose clamp studies in two patients. IMCL and intrahepatic lipid content were measured by 1H magnetic resonance spectroscopy. All measurements were obtained before and during 2-10 months of leptin therapy. RESULTS - Glycemic control and lipoprotein levels markedly improved with leptin therapy in the two diabetic patients, and a slight improvement in lipoprotein levels was seen in the nondiabetic patients. Insulin stimulated glucose uptake during 60-120 min of the euglycemic clamp studies, and the rate of glucose disappearance during the insulin tolerance test nearly doubled with leptin therapy. As compared with the baseline period, after 8-10 months of leptin therapy, the mean intrahepatic lipid content was reduced by ∼80{\%} and the IMCL content was reduced by ∼42{\%}. CONCLUSIONS - Reduction in IMCL and intrahepatic lipid content may partly explain leptin-induced improvement in insulin sensitivity in patients with generalized lipodystrophy.",
author = "Vinaya Simha and Szczepaniak, {Lidia S.} and Wagner, {Anthony J.} and Depaoli, {Alex M.} and Abhimanyu Garg",
year = "2003",
month = "1",
day = "1",
doi = "10.2337/diacare.26.1.30",
language = "English (US)",
volume = "26",
pages = "30--35",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy

AU - Simha, Vinaya

AU - Szczepaniak, Lidia S.

AU - Wagner, Anthony J.

AU - Depaoli, Alex M.

AU - Garg, Abhimanyu

PY - 2003/1/1

Y1 - 2003/1/1

N2 - OBJECTIVE - To investigate whether leptin-induced improvements in glycemic control, hyperlipidemia, and insulin sensitivity in hypoleptinemic patients with generalized lipodystrophies are accompanied by reduction in intrahepatic and intramyocellular lipid (IMCL) accumulation. RESEARCH DESIGN AND METHODS - We examined the effects 8-10 months of subcutaneous leptin replacement therapy on insulin sensitivity, IMCL, and intrahepatic lipid content in two patients with acquired generalized lipodystrophy and one patient with congenital generalized lipodystrophy. All patients had extreme lack of body fat, low plasma leptin levels, and elevated serum triglycerides, but only two had diabetes. Insulin sensitivity was measured by a high-dose (0.2 IU/kg) insulin tolerance test, as well as by hyperinsulinemic-euglycemic glucose clamp studies in two patients. IMCL and intrahepatic lipid content were measured by 1H magnetic resonance spectroscopy. All measurements were obtained before and during 2-10 months of leptin therapy. RESULTS - Glycemic control and lipoprotein levels markedly improved with leptin therapy in the two diabetic patients, and a slight improvement in lipoprotein levels was seen in the nondiabetic patients. Insulin stimulated glucose uptake during 60-120 min of the euglycemic clamp studies, and the rate of glucose disappearance during the insulin tolerance test nearly doubled with leptin therapy. As compared with the baseline period, after 8-10 months of leptin therapy, the mean intrahepatic lipid content was reduced by ∼80% and the IMCL content was reduced by ∼42%. CONCLUSIONS - Reduction in IMCL and intrahepatic lipid content may partly explain leptin-induced improvement in insulin sensitivity in patients with generalized lipodystrophy.

AB - OBJECTIVE - To investigate whether leptin-induced improvements in glycemic control, hyperlipidemia, and insulin sensitivity in hypoleptinemic patients with generalized lipodystrophies are accompanied by reduction in intrahepatic and intramyocellular lipid (IMCL) accumulation. RESEARCH DESIGN AND METHODS - We examined the effects 8-10 months of subcutaneous leptin replacement therapy on insulin sensitivity, IMCL, and intrahepatic lipid content in two patients with acquired generalized lipodystrophy and one patient with congenital generalized lipodystrophy. All patients had extreme lack of body fat, low plasma leptin levels, and elevated serum triglycerides, but only two had diabetes. Insulin sensitivity was measured by a high-dose (0.2 IU/kg) insulin tolerance test, as well as by hyperinsulinemic-euglycemic glucose clamp studies in two patients. IMCL and intrahepatic lipid content were measured by 1H magnetic resonance spectroscopy. All measurements were obtained before and during 2-10 months of leptin therapy. RESULTS - Glycemic control and lipoprotein levels markedly improved with leptin therapy in the two diabetic patients, and a slight improvement in lipoprotein levels was seen in the nondiabetic patients. Insulin stimulated glucose uptake during 60-120 min of the euglycemic clamp studies, and the rate of glucose disappearance during the insulin tolerance test nearly doubled with leptin therapy. As compared with the baseline period, after 8-10 months of leptin therapy, the mean intrahepatic lipid content was reduced by ∼80% and the IMCL content was reduced by ∼42%. CONCLUSIONS - Reduction in IMCL and intrahepatic lipid content may partly explain leptin-induced improvement in insulin sensitivity in patients with generalized lipodystrophy.

UR - http://www.scopus.com/inward/record.url?scp=0043172530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043172530&partnerID=8YFLogxK

U2 - 10.2337/diacare.26.1.30

DO - 10.2337/diacare.26.1.30

M3 - Article

VL - 26

SP - 30

EP - 35

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 1

ER -